Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 167064, 6 pages
http://dx.doi.org/10.1155/2015/167064
Review Article

Treatment of Bullous Systemic Lupus Erythematosus

1Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China
2Department of Pathology, The First Hospital of Xiamen University, Xiamen 361003, China
3Department of Immunology, College of Medicine, Xiamen University, Xiamen 361102, China

Received 5 August 2014; Accepted 21 August 2014

Academic Editor: Jianying Zhang

Copyright © 2015 Lihua Duan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Yung and A. Oakley, “Bullous systemic lupus erythematosus,” The Australasian Journal of Dermatology, vol. 41, no. 4, pp. 234–237, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Rothfield, R. D. Sontheimer, and M. Bernstein, “Lupus erythematosus: systemic and cutaneous manifestations,” Clinics in Dermatology, vol. 24, no. 5, pp. 348–362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Tebbe, “Clinical course and prognosis of cutaneous lupus erythematosus,” Clinics in Dermatology, vol. 22, no. 2, pp. 121–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. P. Hall III, T. J. Lawley, and S. I. Katz, “Bullous eruption of systemic lupus erythematosus,” Journal of the American Academy of Dermatology, vol. 7, no. 6, pp. 797–799, 1982. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Walling and R. Sontheimer, “Cutaneous lupus erythematosus: issues in diagnosis and treatment,” American Journal of Clinical Dermatology, vol. 10, no. 6, pp. 365–381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Vassileva, “Bullous systemic lupus erythematosus,” Clinics in Dermatology, vol. 22, no. 2, pp. 129–138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Camisa and H. M. Sharma, “Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature,” Journal of the American Academy of Dermatology, vol. 9, no. 6, pp. 924–933, 1983. View at Publisher · View at Google Scholar · View at Scopus
  8. W. R. Gammon and R. A. Briggaman, “Bullous SLE: A phenotypically distinctive but immunologically heterogeneous bullous disorder,” Journal of Investigative Dermatology, vol. 100, no. 1, pp. 28S–34S, 1993. View at Google Scholar · View at Scopus
  9. C. Grover, A. Khurana, S. Sharma, and A. Singal, “Bullous systemic lupus erythematosus,” Indian Journal of Dermatology, vol. 58, no. 6, p. 492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Rassbach, N. Shah, and A. Davis, “A 6-year-old girl with extensive bullous skin lesions,” Pediatric Annals, vol. 41, no. 6, pp. 229–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Lalova, K. Pramatarov, and S. Vassileva, “Facial bullous systemic lupus erythematosus,” International Journal of Dermatology, vol. 36, no. 5, pp. 369–371, 1997. View at Google Scholar · View at Scopus
  12. T. Tsuchida, M. Furue, T. Kashiwado, and Y. Ishibashi, “Bullous systemic lupus erythematosus with cutaneous mucinosis and leukocytoclastic vasculitis,” Journal of the American Academy of Dermatology, vol. 31, no. 2, part 2, pp. 387–390, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Neri, M. Mosca, E. Bernacchi, and S. Bombardieri, “A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone,” Lupus, vol. 8, no. 3, pp. 240–243, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. K. L. Liu, J. L. Shen, C. S. Yang, and Y. Chen, “Bullous systemic lupus erythematosus in a child responding to dapsone,” Pediatric Dermatology, vol. 31, no. 4, pp. e104–e106, 2014. View at Publisher · View at Google Scholar
  15. R. P. Hall, T. J. Lawley, H. R. Smith, and S. I. Katz, “Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy,” Annals of Internal Medicine, vol. 97, no. 2, pp. 165–170, 1982. View at Publisher · View at Google Scholar · View at Scopus
  16. M. W. Ludgate and D. E. Greig, “Bullous systemic lupus erythematosus responding to dapsone,” The Australasian Journal of Dermatology, vol. 49, no. 2, pp. 91–93, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Patrício, C. Ferreira, M. M. Gomes, and P. Filipe, “Autoimmune bullous dermatoses: a review,” Annals of the New York Academy of Sciences, vol. 1173, pp. 203–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. “Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines,” Arthritis & Rheumatism, vol. 42, no. 9, pp. 1785–1796, 1999.
  19. M. A. Dooley, C. Aranow, and E. M. Ginzler, “Review of ACR renal criteria in systemic lupus erythematosus,” Lupus, vol. 13, no. 11, pp. 857–860, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. B. H. Hahn, M. A. McMahon, A. Wilkinson et al., “American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis,” Arthritis Care & Research, vol. 64, no. 6, pp. 797–808, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. Lang Jr., “Sulfones and sulfonamides in dermatology today,” Journal of the American Academy of Dermatology, vol. 1, no. 6, pp. 479–492, 1979. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Fabbri, C. Cardinali, B. Giomi, and M. Caproni, “Cutaneous lupus erythematosus: diagnosis and management,” The American Journal of Clinical Dermatology, vol. 4, no. 7, pp. 449–465, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Holtman, D. H. Neustadt, J. Klein, and J. P. Callen, “Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency,” Journal of Rheumatology, vol. 17, no. 9, pp. 1222–1225, 1990. View at Google Scholar · View at Scopus
  24. N. P. Burrows, B. S. Bhogal, M. M. Black et al., “Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases,” British Journal of Dermatology, vol. 128, no. 3, pp. 332–338, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Harris-Stith, Q. L. Erickson, D. M. Elston, and K. David-Bajar, “Bullous eruption: a manifestation of lupus erythematosus,” Cutis, vol. 72, no. 1, pp. 31–37, 2003. View at Google Scholar · View at Scopus
  26. C. S. Sirka, T. Padhi, P. Mohanty, D. K. Patel, P. R. Parida, and C. R. Kar, “Bullous systemic lupus erythematosus: response to dapsone in two patients,” Indian Journal of Dermatology, Venereology and Leprology, vol. 71, no. 1, pp. 54–56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. D. Barton, J.-D. Fine, W. R. Gammon, and W. M. Sams Jr., “Bullous systemic lupus erythematosus: an unusual clinical course and detectable circulating autoantibodies to the epidermolysis bullosa acquisita antigen,” Journal of the American Academy of Dermatology, vol. 15, no. 2, part 2, pp. 369–373, 1986. View at Publisher · View at Google Scholar · View at Scopus
  28. G. S. Alarcón, W. M. Sams Jr., D. D. Barton, and J. Reveille, “Bullous lupus erythematosus rash worsened by Dapsone,” Arthritis & Rheumatism, vol. 27, no. 9, pp. 1071–1072, 1984. View at Google Scholar · View at Scopus
  29. A. Kraus, J. Jakez, and A. Palacios, “Dapsone induced sulfone syndrome and systemic lupus exacerbation,” The Journal of Rheumatology, vol. 19, no. 1, pp. 178–180, 1992. View at Google Scholar · View at Scopus
  30. C. E. dos Santos, P. H. I. Velho, F. M. Marques, B. Werner, S. C. Aragão, and A. R. Filho, “Bullous systemic lupus erythematosus in a pregnant woman: a case report,” Revista Brasileira de Reumatologia, vol. 53, no. 5, pp. 438–440, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Nishina, E. Saito, and M. Kinoshita, “Correction of severe leukocytopenia and thrombocytopenia in systemic lupus erythematosus by treatment with dapsone,” The Journal of Rheumatology, vol. 24, no. 4, pp. 811–812, 1997. View at Google Scholar · View at Scopus
  32. M. A. Meyerson and P. R. Cohen, “Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus,” Mayo Clinic Proceedings, vol. 69, no. 12, pp. 1159–1162, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Moss and P. J. Hamilton, “Thrombocytopenia in systemic lupus erythematosus responsive to dapsone,” British Medical Journal, vol. 297, no. 6643, p. 266, 1988. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Alsanafi, C. Kovarik, A. L. Mermelstein, and V. P. Werth, “Rituximab in the treatment of bullous systemic lupus erythematosus,” Journal of Clinical Rheumatology, vol. 17, no. 3, pp. 142–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. W. W. Chatham and R. P. Kimberly, “Treatment of lupus with corticosteroids,” Lupus, vol. 10, no. 3, pp. 140–147, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. N. Singh, C. M. Adya, K. K. Verma, A. Kumar, and A. N. Malaviya, “Dapsone in cutaneous lesions of SLE: an open study,” The Journal of the Association of Physicians of India, vol. 40, no. 11, pp. 735–736, 1992. View at Google Scholar · View at Scopus
  37. M. Tincopa, K. B. Puttgen, S. Sule, B. A. Cohen, and M. R. Gerstenblith, “Bullous lupus: an unusual initial presentation of systemic lupus erythematosus in an adolescent girl,” Pediatric Dermatology, vol. 27, no. 4, pp. 373–376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C.-C. Mok and C.-S. Lau, “Dapsone syndrome in cutaneous lupus erythematosus,” The Journal of Rheumatology, vol. 23, no. 4, pp. 766–768, 1996. View at Google Scholar · View at Scopus
  39. K. Tsutsui, T. Imai, N. Hatta, H. Sakai, M. Takata, and K. Takehara, “Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy,” Journal of the American Academy of Dermatology, vol. 35, no. 2, pp. 313–315, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. N. I. Stahl, “Progressive multifocal leukoencephalopathy in a minimally immunosuppressed patient with systemic lupus erythematosus treated with dapsone,” The Journal of Rheumatology, vol. 35, no. 4, pp. 725–727, 2008. View at Google Scholar · View at Scopus
  41. S. Ramiro, C. Gaujoux-Viala, J. L. Nam et al., “Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 73, no. 3, pp. 529–535, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. M.-E. Ariza, M. V. Williams, and H. K. Wong, “Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application,” Clinical Immunology, vol. 146, no. 2, pp. 131–139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. S. Raut, R. H. Prabhu, and V. B. Patravale, “Psoriasis clinical implications and treatment: a review,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 30, no. 3, pp. 183–216, 2013. View at Google Scholar · View at Scopus
  44. J. P. Terdiman, C. B. Gruss, J. J. Heidelbaugh, S. Sultan, and Y. T. Falck-Ytter, “American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease,” Gastroenterology, vol. 145, no. 6, pp. 1459–1463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. He, H. Qian, Y. Liu, L. Duan, Y. Li, and G. Shi, “The roles of regulatory B cells in cancer,” Journal of Immunology Research, vol. 2014, Article ID 215471, 7 pages, 2014. View at Publisher · View at Google Scholar
  46. Y. Bao and X. Cao, “The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review,” Journal of Autoimmunity, vol. 56, pp. 10–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. F. B. Vincent, D. Saulep-Easton, W. A. Figgett, K. A. Fairfax, and F. Mackay, “The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity,” Cytokine & Growth Factor Reviews, vol. 24, no. 3, pp. 203–215, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. F. B. Vincent, E. F. Morand, P. Schneider, and F. Mackay, “The BAFF/APRIL system in SLE pathogenesis,” Nature Reviews: Rheumatology, vol. 10, no. 6, pp. 365–373, 2014. View at Publisher · View at Google Scholar
  49. J. H. Anolik, “B cell biology: implications for treatment of systemic lupus erythematosus,” Lupus, vol. 22, no. 4, pp. 342–349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Cobo-Ibáñez, E. Loza-Santamaría, J. M. Pego-Reigosa et al., “Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review,” Seminars in Arthritis and Rheumatism, vol. 44, no. 2, pp. 175–185, 2014. View at Publisher · View at Google Scholar
  51. P. Emery, A. Sebba, and T. W. J. Huizinga, “Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 72, no. 12, pp. 1897–1904, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Kuhn, C. Specker, T. Ruzicka, and P. Lehmann, “Methotrexate treatment for refractory subacute cutaneous lupus erythematosus,” Journal of the American Academy of Dermatology, vol. 46, no. 4, pp. 600–603, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. I. Bohm, M. Uerlich, and R. Bauer, “Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate,” Dermatology, vol. 194, no. 3, pp. 307–308, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. I. B. Boehm, G. A. Boehm, and R. Bauer, “Management of cutaneous lupus erythematosus with low dose methotrexate: indication for modulation of inflammatory mechanisms,” Rheumatology International, vol. 18, no. 2, pp. 59–62, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Sato, “Methotrexate therapy in systemic lupus erythematosus,” Lupus, vol. 10, no. 3, pp. 162–164, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. D. F. Sebaratnam and D. F. Murrell, “Bullous systemic lupus erythematosus,” Dermatologic Clinics, vol. 29, no. 4, pp. 649–653, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Malcangi, G. Brandozzi, M. Giangiacomi, M. Zampetti, and M. G. Danieli, “Bullous SLE: response to methotrexate and relationship with disease activity,” Lupus, vol. 12, no. 1, pp. 63–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. V. Bykerk, J. Sampalis, J. M. Esdaile et al., “A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus,” The New England Journal of Medicine, vol. 324, no. 3, pp. 150–154, 1991. View at Publisher · View at Google Scholar · View at Scopus
  59. G. J. Pons-Estel, G. S. Alarcón, G. McGwin Jr. et al., “Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort,” Arthritis Care and Research, vol. 61, no. 6, pp. 830–839, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. J. P. Callen and J. Klein, “Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients,” Arthritis and Rheumatism, vol. 31, no. 8, pp. 1007–1013, 1988. View at Publisher · View at Google Scholar · View at Scopus